Pages that link to "Q33539857"
Jump to navigation
Jump to search
The following pages link to RAS and leukemia: from basic mechanisms to gene-directed therapy (Q33539857):
Displaying 50 items.
- RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures (Q27852887) (← links)
- Ras-induced cellular events (review) (Q28138814) (← links)
- The use of non-tumor data in cancer risk assessment: reflections on butadiene, vinyl chloride, and benzene (Q30781327) (← links)
- In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia (Q33348021) (← links)
- Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure (Q33376638) (← links)
- Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia (Q33389328) (← links)
- Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation (Q33615619) (← links)
- RAS inhibitors in hematologic cancers: biologic considerations and clinical applications (Q33819356) (← links)
- Prognostic impact of RAS mutations in patients with myelodysplastic syndrome (Q33871210) (← links)
- Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia (Q34123842) (← links)
- STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. (Q34284326) (← links)
- Blocking oncogenic Ras signaling for cancer therapy (Q34311585) (← links)
- Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase (Q34329174) (← links)
- Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies (Q34346795) (← links)
- Therapeutic options for acute myelogenous leukemia (Q34380840) (← links)
- Targeted therapies for high-risk acute myeloid leukemia (Q34417569) (← links)
- Evolving therapies: farnesyltransferase inhibitors (Q34457426) (← links)
- Cytokine deregulation in cancer (Q34479801) (← links)
- Cellular signalling pathways: new targets in leukaemia therapy (Q34527660) (← links)
- Prospects for anti-ras drugs (Q34534438) (← links)
- New drugs for therapy of AML. (Q34565036) (← links)
- Analysis of Ras-induced overproliferation in Drosophila hemocytes. (Q34616733) (← links)
- The search for optimal treatment in relapsed and refractory acute myeloid leukemia (Q34630777) (← links)
- Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. (Q34638143) (← links)
- Ras family genes: an interesting link between cell cycle and cancer (Q34736658) (← links)
- Advanced-phase chronic myeloid leukemia (Q35058707) (← links)
- Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia (Q35186888) (← links)
- Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease (Q35615842) (← links)
- The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases (Q35738921) (← links)
- Novel therapies for myelodysplastic syndromes (Q35829958) (← links)
- Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies (Q35872060) (← links)
- Investigational agents in myeloid disorders (Q35909283) (← links)
- Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action (Q35932017) (← links)
- Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease (Q36056927) (← links)
- Emerging drugs for the treatment of myelodysplastic syndrome (Q36219655) (← links)
- Tipifarnib: farnesyl transferase inhibition at a crossroads (Q36407429) (← links)
- Ras as a therapeutic target in hematologic malignancies (Q36866611) (← links)
- Cooperating gene mutations in acute myeloid leukemia: a review of the literature. (Q37089717) (← links)
- Experimental non-ATP-competitive therapies for chronic myelogenous leukemia (Q37103609) (← links)
- Cause and consequences of genetic and epigenetic alterations in human cancer. (Q37511752) (← links)
- The challenge of risk stratification in acute myeloid leukemia with normal karyotype (Q37671778) (← links)
- Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives (Q37815040) (← links)
- Mouse models for pre-clinical drug testing in leukemia (Q38937610) (← links)
- Acute sensitivity of the oral mucosa to oncogenic K-ras. (Q39868878) (← links)
- Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia (Q40055219) (← links)
- Reovirus as a novel oncolytic agent (Q40365039) (← links)
- Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway (Q40495521) (← links)
- Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia. (Q41535044) (← links)
- LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer (Q41875219) (← links)
- The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'. (Q43633451) (← links)